ESOC 2023 | UKPDS: impact of blood pressure and blood glucose control on long-term stroke and dementia risk

William Whiteley, PhD, MRCP, University of Edinburgh, presents the long-term follow-up findings of the UKPDS trial initiated in 1977, which tested blood-pressure-lowering and glucose-lowering treatments for up to 10 years in over 5000 people with newly diagnosed diabetes. This analysis focused on assessing the impact of blood pressure and blood glucose control on the long-term risk of stroke and dementia. The primary objective was to investigate whether stricter control of these factors would reduce the risk of developing dementia later in life. The results, presented in Munich, showed that there was no statistically significant difference in the incidence of stroke or dementia among the treatment groups over the 44 year study period. However, due to the relatively small number of participants in each intervention, it was not possible to definitively conclude whether there were potential beneficial or harmful effects.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.